£35.9M
Koch Disruptive Technologies led the Series B round to support the commercialisation of the Veros diagnostics platform.
Sense Biodetection
Sense Biodetection develops rapid molecular diagnostic tests for decentralized healthcare.
£35.9MTotal raised
Sense Biodetection is a global molecular diagnostics company that develops instrument free rapid molecular tests to improve healthcare access. The firm is preparing to launch its Veros platform, starting with a COVID-19 test.
Categories
Team
HL
Harry Lamble
CEO
Harry brings executive and founding experience from diagnostics and therapeutics companies, including Sense Biodetection and Oxford BioTherapeutics. He previously held a research development director role at the Institute of Biomedical Engineering at Imperial College London.
LinkedIn